| Date | Time | Source | Headline | Symbol | Company |
| 10/25/2007 | 4:34PM | Edgar (US Regulatory) | Gilead Sciences Inc - Current report filing (8-K) | NASDAQ:GILD | Gilead Sciences Inc |
| 10/23/2007 | 5:02PM | PR Newswire (US) | /C O R R E C T I O N -- Deloitte/ | NASDAQ:GILD | |
| 10/23/2007 | 9:02AM | PR Newswire (US) | SIRIUS Satellite Named Fastest Growing Company in Deloitte's 2007 Technology Fast 500 Ranking | NASDAQ:GILD | Gilead Sciences Inc |
| 10/22/2007 | 4:59PM | Edgar (US Regulatory) | Gilead Sciences Inc - Current report filing (8-K) | NASDAQ:GILD | Gilead Sciences Inc |
| 10/19/2007 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on RIMM, GM, RIG, GILD, and HOG | NASDAQ:GILD | Gilead Sciences Inc |
| 10/18/2007 | 4:12PM | Edgar (US Regulatory) | Gilead Sciences Inc - Current report filing (8-K) | NASDAQ:GILD | Gilead Sciences Inc |
| 10/18/2007 | 4:12PM | Edgar (US Regulatory) | Gilead Sciences Inc - Current report filing (8-K) | NASDAQ:GILD | Gilead Sciences Inc |
| 10/18/2007 | 2:42PM | PR Newswire (US) | European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 m | NASDAQ:GILD | Gilead Sciences Inc |
| 10/17/2007 | 8:00AM | PR Newswire (US) | Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once- | NASDAQ:GILD | Gilead Sciences Inc |
| 10/05/2007 | 4:12PM | Edgar (US Regulatory) | Gilead Sciences Inc - Prospectus filed pursuant to Rule 424(b)(7) (424B7) | NASDAQ:GILD | Gilead Sciences Inc |
| 10/05/2007 | 4:12PM | Edgar (US Regulatory) | Gilead Sciences Inc - Prospectus filed pursuant to Rule 424(b)(7) (424B7) | NASDAQ:GILD | Gilead Sciences Inc |
| 09/28/2007 | 1:33PM | Edgar (US Regulatory) | Gilead Sciences Inc (Other) (424B7) | NASDAQ:GILD | Gilead Sciences Inc |
| 08/29/2007 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on BA, VZ, BIDU, GILD, and ELNK | NASDAQ:GILD | Gilead Sciences Inc |
| 08/15/2007 | 4:15PM | Business Wire | Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug Candidates for Pulmonary Disease | NASDAQ:GILD | Gilead Sciences Inc |
| 08/08/2007 | 10:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on XOM, RIMM, ANF, GILD, and EQ | NASDAQ:GILD | Gilead Sciences Inc |
| 07/31/2007 | 4:15PM | Business Wire | Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan | NASDAQ:GILD | Gilead Sciences Inc |
| 07/23/2007 | 8:30AM | Business Wire | 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At Inter | NASDAQ:GILD | Gilead Sciences Inc |
| 07/20/2007 | 9:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on AMD, GILD, MDT, DE, and IACI | NASDAQ:GILD | Gilead Sciences Inc |
| 07/19/2007 | 4:05PM | Business Wire | Gilead Sciences Announces Second Quarter 2007 Financial Results | NASDAQ:GILD | Gilead Sciences Inc |
| 07/12/2007 | 4:05PM | Business Wire | Gilead Sciences to Release Second Quarter 2007 Financial Results on Thursday, July 19, 2007 | NASDAQ:GILD | Gilead Sciences Inc |
| 07/09/2007 | 4:30PM | Business Wire | Gilead Announces Expanded Access Program for Aztreonam Lysine for Inhalation for Patients with Cystic Fibrosis | NASDAQ:GILD | Gilead Sciences Inc |
| 06/25/2007 | 8:30AM | Business Wire | Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint | NASDAQ:GILD | Gilead Sciences Inc |
| 06/21/2007 | 4:30PM | Business Wire | Gilead Sciences to Present at Two Upcoming Investor Conferences | NASDAQ:GILD | Gilead Sciences Inc |
| 06/19/2007 | 8:30AM | Business Wire | Gilead Sciences Completes $1 Billion Stock Repurchase Program | NASDAQ:GILD | Gilead Sciences Inc |
| 06/15/2007 | 5:26PM | Business Wire | Gilead Sciences to Host Conference Call to Discuss the U.S. Food and Drug Administration Approval of Letairis(TM) | NASDAQ:GILD | Gilead Sciences Inc |
| 06/15/2007 | 5:21PM | Business Wire | U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatme | NASDAQ:GILD | Gilead Sciences Inc |
| 06/15/2007 | 11:59AM | PR Newswire (US) | Seven Summits Research Releases Comments on GS, CVX, CMCSA, GILD, and VRTX | NASDAQ:GILD | Gilead Sciences Inc |
| 06/06/2007 | 5:35PM | Business Wire | Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint | NASDAQ:GILD | Gilead Sciences Inc |
| 06/06/2007 | 4:30PM | Business Wire | Gilead Sciences to Present at the Goldman Sachs 28th Annual Healthcare Conference on Wednesday, June 13 | NASDAQ:GILD | Gilead Sciences Inc |
| 05/30/2007 | 4:30PM | Business Wire | Gilead Sciences' Executive Vice President, Commercial Operations Establishes Rule 10b5-1 Stock Trading Plan | NASDAQ:GILD | Gilead Sciences Inc |